August 22, 2017 โ LivaNova PLC announced its Perceval sutureless aortic heart valve received approval from the Centers ...
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device, developed in response to the global unmet need for effective, low-cost, front-line screening of cardiac disease in both symptomatic and asymptomatic patients. MyoVista measures the heart's energy during each heartbeat using a type of advanced signal processing known as Continuous Wavelet Transform (CWT).
The U.S. Department of Health and Human Services (HHS), Office for Civil Rights (OCR) recently launched a revised web tool that puts important information on cybersecurity breaches into the hands of individuals. The tool is designed to empower them to better identify recent breaches of health information and to learn how all breaches of health information are investigated and successfully resolved.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an MR conditional quadripolar (QP) cardiac resynchronization therapy pacemaker (CRT-P) with MRI (magnetic resonance imaging) AutoDetect technology.
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT) in patients implanted with the Resolute Onyx Drug-Eluting Stent (DES) during percutaneous coronary intervention (PCI). Designed to evaluate clinical DAPT outcomes between two DES for the first time ever, the RESOLUTE ONYX ONE-MONTH DAPT Study intends to help inform DAPT guidelines for newer-generation DES that currently favor bare-metal stents (BMS) for patients with stable ischemic heart disease who might require a shorter dual antiplatelet regimen.
August 18, 2017 โ The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document with ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
August 17, 2017 โ Cybersecurity has become a growing concern in healthcare as patient data, medical systems and ...
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge technology to Houston Methodist that is not currently available in the Texas Medical Center. This agreement will provide innovative, world-class medical technology to Houston Methodist Hospital and all of its community hospital facilities.
ScImage Inc. was recently awarded a new DIN-PACS IV (Digital Imaging Network/Picture Archiving and Communications System) contract by the U.S. government. The contract is potentially valued up to $400 million, and the terms include one five-year base period and one five-year option period.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology ...
August 16, 2017 โ BioCardia Inc. recently announced completion of treatment for the 10-patient roll-in cohort for the ...
August 16, 2017 โ A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
August 16, 2017 โ The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number of ...
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast agents during MRI scans. Emerging research suggests gadolinium-based contrast agents, injected in a patient's veins to brighten tissues in MRI images, accumulate in the brain. More than 300 million doses of such drugs have been administered since their introduction in 1987.
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) in July to initiate a pivotal clinical trial of the SurVeil drug-coated balloon (DCB). The randomized trial will evaluate the SurVeil DCB for treatment for peripheral artery disease (PAD) in the upper leg compared to the Medtronic IN.PACT Admiral DCB.